Integrated network pharmacology, molecular docking, and in vitro experiments reveal the multi-target mechanism of Esculin against gastric cancer
Authors: He, Hui; Guo, Jianjin; Zhang, Yuan; Luo, Jiajia; Jiang, Jianqi; Wang, Rong; Wei, Benjun
Source journal: Journal of computer-aided molecular design (2026-11-20)
DOI: 10.1007/s10822-026-00983-3
Abstract
Gastric cancer (GC) remains one of the most common malignancies worldwide, and although Esculin, a major coumarin from Cortex Fraxini, has shown antitumor potential, its multi-target mechanism against GC has not been systematically elucidated. Therefore, this study integrated network pharmacology, molecular docking, 100-ns molecular dynamics (MD) simulation, bioinformatics analysis and in vitro experiments to investigate the anti-GC mechanism of Esculin. Network pharmacology identified 396 potential Esculin targets and 9,408 GC-related targets, yielding 214 common targets; PPI network analysis highlighted AKT1, SRC, EGFR, and MMP2 as core targets, and KEGG enrichment implicated PI3K-Akt signaling, MAPK cascades, matrix metalloproteinase activation, and apoptosis. Molecular docking showed that Esculin bound to MMP2, EGFR, AKT1, and SRC with binding energies of - 8.69, - 8.59, - 7.84, and - 6.45 kcal/mol, respectively, and MD simulations confirmed that the MMP2-, EGFR-, and AKT1-Esculin complexes remained stable over 100 ns, with concentrated low-energy basins in free energy landscape analysis. Bioinformatics analysis revealed that all four core targets were highly expressed in GC, and MMP2 expression was associated with poor prognosis, advanced stage, and macrophage infiltration. In vitro, Esculin showed low toxicity to normal gastric mucosal GES-1 cells but significantly inhibited proliferation, colony formation, invasion, and migration and induced apoptosis in AGS and MKN-45 GC cells, with AGS cells being more sensitive; Western blot further showed that Esculin decreased p-PI3K and p-Akt levels without altering total PI3K and Akt expression. Collectively, these findings indicate that Esculin exerts multi-target anti-GC activity, with its core mechanism closely related to inhibition of PI3K-Akt pathway activation, induction of apoptosis, and suppression of invasion and migration, providing a theoretical and experimental basis for developing Esculin as a candidate anti-GC drug.
Related topics
Related open access articles
- Development and Validation Molecular Docking Analysis of Human serum albumin (HSA)
- Facing COVID-19 via anti-inflammatory mechanism of action: Molecular docking and Pharmacokinetic studies of six anti-inflammatory compounds derived from Passiflora edulis
- Computational analysis by molecular docking of thirty alkaloid compounds from medicinal plants as potent inhibitors of SARS-CoV-2 main protease
- Curcumin and pipernonaline to curb diabetes the natural way: A molecular modeling, docking and dynamics simulation study
- DENSITY FUNCTIONAL THEORY ANALYSIS AND MOLECULAR DOCKING EVALUATION OF 8-CHLOROQUINOLINE 2-CARBALDEHYDE
- Thermochemical, DFT, Molecular Docking and Pharmacokinetic Studies of Methyl β-D-galactopyranoside Esters
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.